Ahmed Hafez Allam

Ahmed Hafez Allam

Auto-generated profile, based on publicly available information

Ahmed Hafez Allam

Faculty of Medicine, Menoufia University, Menoufia, Egypt

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in European Radiology
Verified
Journal Article
Open access
PDF file
AAAhmed Hafez Allam
Ahmed Hafez Allam
NENael Kamel Eltewacy
Nael Kamel Eltewacy
YAYasmeen Jamal Alabdallat
Yasmeen Jamal Alabdallat
TOTarek A. Owais
Tarek A. Owais
SSSaif Salman
Saif Salman
MEMahmoud A. Ebada
Mahmoud A. Ebada
Objectives: We aimed to assess undergraduate medical students’ knowledge, attitude, and perception regarding artificial intelligence (AI) in medicine. Methods: A multi-national, multi-center cross-sectional study was conducted from March to April 2022, targeting undergraduate medical students in nine Arab countries. The study utilized a web-based questionnaire, with data collection carried out with the help of national leaders and local collaborators. Logistic regression analysis was performed to identify predictors of knowledge, attitude, and perception among the participants. Additionally, cluster analysis was employed to identify shared patterns within their responses. Results: Of the 4492 students surveyed, 92.4% had not received formal AI training. Regarding AI and deep learning (DL), 87.1% exhibited a low level of knowledge. Most students (84.9%) believed AI would revolutionize medicine and radiology, with 48.9% agreeing that it could reduce the need for radiologists. Students with high/moderate AI knowledge and training had higher odds of agreeing to endorse AI replacing radiologists, reducing their numbers, and being less likely to consider radiology as a career compared to those with low knowledge/no AI training. Additionally, the majority agreed that AI would aid in the automated detection and diagnosis of pathologies. Conclusions: Arab medical students exhibit a notable deficit in their knowledge and training pertaining to AI. Despite this, they hold a positive perception of AI implementation in medicine and radiology, demonstrating a clear understanding of its significance for the healthcare system and medical curriculum. Clinical relevance statement: This study highlights the need for widespread education and training in artificial intelligence for Arab medical students, indicating its significance for healthcare systems and medical curricula. Key Points: • Arab medical students demonstrate a significant knowledge and training gap when it comes to using AI in the fields of medicine and radiology. • Arab medical students recognize the importance of integrating AI into the medical curriculum. Students with a deeper understanding of AI were more likely to agree that all medical students should receive AI education. However, those with previous AI training were less supportive of this idea. • Students with moderate/high AI knowledge and training displayed increased odds of agreeing that AI has the potential to replace radiologists, reduce the demand for their services, and were less inclined to pursue a career in radiology, when compared to students with low knowledge/no AI training.

6 May 2022 in Joint Bone Spine
Verified
Journal Article
Closed access
MGMohamed Gadelkarim
Mohamed Gadelkarim
MGMohamed Gadelkarim
Mohamed Gadelkarim
AAAhmed Hafez Allam
Ahmed Hafez Allam
AAAhmed K. Awad
Ahmed K. Awad
MSMostafa Shehata
Mostafa Shehata
AAAhmed M. Afifi
Ahmed M. Afifi

29 April 2022 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
MAMahmoud M. Ali
Mahmoud M. Ali
AHAhmed Hafez
Ahmed Hafez
MAMahmoud Shaban Abdelgalil
Mahmoud Shaban Abdelgalil
MHMohammed Tarek Hasan
Mohammed Tarek Hasan
MEMohammed Magdy El-Ghannam
Mohammed Magdy El-Ghannam
MAMohamed Abd-Elgawad
Mohamed Abd-Elgawad
Background: The food and drug administration approved many drugs to treat diabetes mellitus, but those drugs do not have a noticeable effect on weight management. Recently, glucagon-like peptide 1 agonist known as Cotadutide serve as a potent drug in treating type 2 diabetes by reducing blood glucose levels and body weight indices. This study aimed to explore the safety and efficacy of Cotadutide as a treatment for type 2 diabetes individuals. Methods: A comprehensive literature search was done on different databases, including PubMed, Scopus, Web of Science, and Cochrane Library to capture all relevant articles using an established search strategy. The inclusion criteria were randomized controlled trials that assessed the safety and efficacy of Cotadutide versus placebo or any anti-diabetes drugs in patients with type 2 diabetes mellitus and a BMI between 22 kg/m2 and 40 kg/m2. We conducted the analysis using Revman software version 5.4. Results: We found 663 relevant articles. From which nine studies were included and subjected to qualitative analysis and eight for quantitative analysis. The pooled effect showed that Cotadutide was better than placebo in reducing body weight (kg) (Mean difference (MD) = 3.31, p < 0.00001), glycated hemoglobin (HbA1c) (MD = 0.68, p > 0.00001), glucose area under the plasma concentration curve (AUC [0-4 h]) (MD = 30.15, p < 0.00001), and fasting plasma glucose over time (mg/dl) (MD = 31.31, p < 0.00001). Conclusion: Cotadutide is safe and effective in reducing plasma glucose levels, HbA1c and body weight in individuals with type 2 diabetes. Trial registration: The study protocol was registered on PROSPERO (CRD: CRD42021257670).

5 September 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ATAmira Mohamed Taha
Amira Mohamed Taha
ASAhmad Shehata Shaarawy
Ahmad Shehata Shaarawy
MOMohamed Mosad Omar
Mohamed Mosad Omar
KAKhaled Abouelmagd
Khaled Abouelmagd
NSNoran Magdy Shalma
Noran Magdy Shalma
MAMohamed Abd-Elgawad
Mohamed Abd-Elgawad
Background: Omega-3 may alleviate the severity of coronavirus disease 2019 (COVID-19) by reducing the C-reactive protein (CRP) level, a marker for systemic inflammation. Because the scientific evidence indicating such a role is inconsistent, we aimed to evaluate the effect of Omega-3 on CRP change and CRP level in patients with COVID-19.Methods: We conducted a comprehensive search on four databases (PubMed, Web of Science, EMBASE, and Scopus). We included all RCTs comparing Omega-3 with a control group regarding their effect on the CRP levels in patients with COVID-19. We used version two of the Cochrane risk of bias assessment tool to appraise the included studies. We extracted data to an online data extraction sheet. The primary outcomes were CRP change from baseline and CRP serum levels.Results: We included four randomized controlled trials (RCTs) with 274 patients in this study. The overall effect estimate favored Omega-3 over the control group in terms of CRP change from baseline (mean difference (MD) =− 2.53, 95% confidence interval (CI): − 4.40, − 0.66) and CRP serum levels at the end of the study (MD =− 6.24, 95% CI: − 11.93, − 0.54).Conclusion: Omega-3 showed promising effects on systemic inflammation by reducing CRP levels in COVID-19 patients. Based on this finding, we recommend Omega-3 for COVID-19 patients for its anti-inflammatory actions.